Clinical Trial Update: A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating two management strategies for gastrointestinal symptoms in patients newly on Pradaxa (dabigatran) for stroke prevention in non-valvular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2015-10-05